Home  /  Resource Library  /  Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

CLL patients harboring mutated IGHV genes but neither 11q or 17p deletion experience durable remission after frontline FCR